Biotech Company Akero Therapeutics Efruxifermin Shows Promise in Liver Scarring Improvement

Photo of author
Written By Elizabeth Monroe

Akero Therapeutics has experienced a tumultuous journey marked by highs and lows, but recent developments have reignited optimism surrounding its FGF21 analog, efruxifermin. 

Following setbacks from a previous trial failure, Akero has bounced back with promising 96-week data demonstrating significant improvements in liver scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH). 

Positive Data Sparks Investor Enthusiasm

Investors responded enthusiastically to the latest data, driving Akero Therapeutics’ stock price up by a remarkable 62% to $45 in premarket trading. This surge reflects renewed confidence in the potential of efruxifermin following the release of compelling clinical trial results.

Read More: DigitalOcean Holdings Inc (DOCN) Reports Show Solid Revenue Growth and Robust Free Cash Flow in FY 2023

Key Findings from the HARMONY Study

Akero initially published 24-week data from the phase 2b HARMONY trial in 2022, revealing encouraging outcomes for patients treated with efruxifermin. 

Credits: DepositPhotos

Notably, a significant proportion of patients experienced improvements in liver fibrosis without worsening of MASH, compared to those on placebo. 

However, the initial optimism was dampened by setbacks from another efruxifermin trial, which led to a sharp decline in Akero’s stock value.

Encouraging 96-Week Data

Despite the earlier setbacks, Akero has now shared promising 96-week data from the HARMONY study. 

In the high-dose cohort, a remarkable 75% of patients demonstrated a one-stage or more improvement in fibrosis without worsening of MASH, far surpassing the response rate observed in the placebo group. Even in the low-dose cohort, a significant proportion of patients exhibited favorable responses, with a response rate of 46%.

Also Read: Consensus Cloud Solutions (NASDAQ: CCSI) is an Intriguing Investment Opportunity 

Significant Improvement Over Placebo

The disparity between efruxifermin and placebo became more pronounced in patients who achieved a two-stage or more improvement in fibrosis without worsening of MASH. 

Notably, a substantial percentage of patients in both the low and high dose cohorts surpassed this threshold, highlighting the therapeutic potential of efruxifermin in addressing liver scarring in MASH patients.

Expert Commentary and Future Outlook

Dr. Stephen Harrison, medical director of Pinnacle Clinical Research and principal investigator for the HARMONY study, emphasized the significance of the response rates observed in the trial. 

While acknowledging the limitations of cross-trial comparisons, Dr. Harrison lauded the impressive outcomes achieved with efruxifermin, underscoring its potential to address unmet needs in the MASH population.

Safety Profile and Market Response

Akero also provided insights into the safety and tolerability of efruxifermin, reporting a manageable incidence of serious adverse events and treatment discontinuations due to adverse events. 

The overwhelmingly positive data prompted a surge in investor confidence, reflected in the significant increase in Akero’s stock price.

Potential Turning Point

The resurgence of Akero Therapeutics, fueled by promising data from the HARMONY study, signifies a potential turning point in the company’s trajectory. 

Credits: DepositPhotos

With efruxifermin demonstrating substantial improvements in liver scarring in MASH patients, Akero is poised to regain momentum and emerge as a key player in the treatment of metabolic liver diseases. 

As this biotech company continues to advance its clinical programs and explore the full therapeutic potential of efruxifermin, investors remain optimistic about its future prospects and the potential fruit it will yield.

Read Next: Unpacking the Sidus Space Share Rollercoaster


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.